Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(2):236–240. doi: 10.1038/bjc.1997.39

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.

P J Johnson 1, N Leung 1, P Cheng 1, C Welby 1, W T Leung 1, W Y Lau 1, S Yu 1, S Ho 1
PMCID: PMC2063272  PMID: 9010032

Abstract

The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients with AFP levels > or = 50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis of conventionally defined criteria. On entry into the study, 53 patients had an AFP concentration > = or 50 ng ml-1 and the 'hepatoma-specific' AFP isoform was detected in 26 of these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two 'probable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18 months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed 'probable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only 41.5% using the conventional 'total' AFP test. Application of this test for the 'hepatoma-specific' AFP markedly increases the positive predictive value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination.

Full text

PDF
236

Images in this article

238Figure 3
on p.238

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert E., Feller E. R. Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology. 1978 May;74(5 Pt 1):856–858. [PubMed] [Google Scholar]
  2. Aoyagi Y., Isemura M., Yosizawa Z., Suzuki Y., Sekine C., Ono T., Ichida F. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta. 1985 Aug 23;830(3):217–223. doi: 10.1016/0167-4838(85)90277-8. [DOI] [PubMed] [Google Scholar]
  3. Aoyagi Y., Suzuki Y., Igarashi K., Saitoh A., Oguro M., Yokota T., Mori S., Suda T., Isemura M., Asakura H. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer. 1993 Mar;67(3):486–492. doi: 10.1038/bjc.1993.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aoyagi Y., Suzuki Y., Isemura M., Soga K., Ozaki T., Ichida T., Inoue K., Sasaki H., Ichida F. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gan. 1984 Sep;75(9):809–815. [PubMed] [Google Scholar]
  5. Bloomer J. R., Waldmann T. A., McIntire K. R., Klatskin G. alpha-fetoprotein in noneoplastic hepatic disorders. JAMA. 1975 Jul 7;233(1):38–41. doi: 10.1001/jama.233.1.38. [DOI] [PubMed] [Google Scholar]
  6. Buamah P. K., Harris R., James O. F., Skillen A. W. Lentil-lectin-reactive alpha-fetoprotein in the differential diagnosis of benign and malignant liver disease. Clin Chem. 1986 Nov;32(11):2083–2084. [PubMed] [Google Scholar]
  7. Burditt L. J., Johnson M. M., Johnson P. J., Williams R. Detection of hepatocellular carcinoma-specific alpha-fetoprotein by isoelectric focusing. Cancer. 1994 Jul 1;74(1):25–29. doi: 10.1002/1097-0142(19940701)74:1<25::aid-cncr2820740106>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  8. Colombo M., de Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M., Donato M. F., Piva A., Di Carlo V., Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991 Sep 5;325(10):675–680. doi: 10.1056/NEJM199109053251002. [DOI] [PubMed] [Google Scholar]
  9. Curley S. A., Izzo F., Gallipoli A., de Bellis M., Cremona F., Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg. 1995 Sep;222(3):375–383. doi: 10.1097/00000658-199509000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Du M. Q., Hutchinson W. L., Johnson P. J., Williams R. Differential alpha-fetoprotein lectin binding in hepatocellular carcinoma. Diagnostic utility at low serum levels. Cancer. 1991 Jan 15;67(2):476–480. doi: 10.1002/1097-0142(19910115)67:2<476::aid-cncr2820670226>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  11. Govindarajan S., Fong T. L., Ashcavai M. Concanavalin A affinity of alpha-fetoprotein. Its use in differentiating tumors. Am J Clin Pathol. 1987 Dec;88(6):722–724. doi: 10.1093/ajcp/88.6.722. [DOI] [PubMed] [Google Scholar]
  12. Ho S., Cheng P., Yuen J., Chan A., Leung N., Yeo W., Leung T., Lau W. Y., Li A. K., Johnson P. J. Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. Br J Cancer. 1996 Apr;73(8):985–988. doi: 10.1038/bjc.1996.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Johnson P. J., Ho S., Cheng P., Chan A., Leung T., Yuen J. Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. Cancer. 1995 Apr 1;75(7):1663–1668. doi: 10.1002/1097-0142(19950401)75:7<1663::aid-cncr2820750717>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  14. Johnson P. J., Portmann B., Williams R. Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J. 1978 Sep 2;2(6138):661–663. doi: 10.1136/bmj.2.6138.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Krusius T., Ruoslahti E. Carbohydrate structure of the concanavalin A molecular variants of alpha-fetoprotein. J Biol Chem. 1982 Apr 10;257(7):3453–3457. [PubMed] [Google Scholar]
  16. Lee H. S., Chung Y. H., Kim C. Y. Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology. 1991 Jul;14(1):68–72. doi: 10.1002/hep.1840140112. [DOI] [PubMed] [Google Scholar]
  17. Liaw Y. F., Tai D. I., Chu C. M., Lin D. Y., Sheen I. S., Chen T. J., Pao C. C. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986 Feb;90(2):263–267. doi: 10.1016/0016-5085(86)90919-4. [DOI] [PubMed] [Google Scholar]
  18. Lok A. S., Lai C. L. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989 Jan;9(1):110–115. doi: 10.1002/hep.1840090119. [DOI] [PubMed] [Google Scholar]
  19. Oka H., Kurioka N., Kim K., Kanno T., Kuroki T., Mizoguchi Y., Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990 Oct;12(4 Pt 1):680–687. doi: 10.1002/hep.1840120411. [DOI] [PubMed] [Google Scholar]
  20. Oka H., Tamori A., Kuroki T., Kobayashi K., Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994 Jan;19(1):61–66. [PubMed] [Google Scholar]
  21. Sato Y., Nakata K., Kato Y., Shima M., Ishii N., Koji T., Taketa K., Endo Y., Nagataki S. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993 Jun 24;328(25):1802–1806. doi: 10.1056/NEJM199306243282502. [DOI] [PubMed] [Google Scholar]
  22. Taketa K., Izumi M., Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci. 1983;417:61–68. doi: 10.1111/j.1749-6632.1983.tb32849.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES